KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bausch Health Companies (BHC) Common Equity (2016 - 2025)

Bausch Health Companies (BHC) has disclosed Common Equity for 17 consecutive years, with $377.0 million as the latest value for Q4 2025.

  • Quarterly Common Equity rose 217.08% to $377.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $377.0 million through Dec 2025, up 217.08% year-over-year, with the annual reading at $377.0 million for FY2025, 217.08% up from the prior year.
  • Common Equity hit $377.0 million in Q4 2025 for Bausch Health Companies, up from $356.0 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $433.0 million in Q3 2022 to a low of -$611.0 million in Q2 2021.
  • Historically, Common Equity has averaged -$16.2 million across 5 years, with a median of -$103.0 million in 2021.
  • Biggest five-year swings in Common Equity: skyrocketed 864.71% in 2022 and later plummeted 292.68% in 2024.
  • Year by year, Common Equity stood at -$34.0 million in 2021, then surged by 864.71% to $260.0 million in 2022, then plummeted by 131.54% to -$82.0 million in 2023, then tumbled by 292.68% to -$322.0 million in 2024, then soared by 217.08% to $377.0 million in 2025.
  • Business Quant data shows Common Equity for BHC at $377.0 million in Q4 2025, $356.0 million in Q3 2025, and $147.0 million in Q2 2025.